Clinical outcome endpoints in heart failure trials: A European Society of Cardiology Heart Failure Association consensus document

European Journal of Heart Failure

Volumn 15, Issue 10, 2013, Pages 1082-1094

  Zannad, Faiez ^a   Stein, Kenneth ^ae   Garcia, Angeles Alonso ^b   Anker, Stefan D ^c   Armstrong, Paul W ^d   Calvo, Gonzalo ^e   Cleland, John G F ^f   Cohn, Jay N ^g   Dickstein, Kenneth ^h   Domanski, Michael J ⁱ   Ekman, Inger ^j   Filippatos, Gerasimos S ^k   Gheorghiade, Mihai ^l   Hernandez, Adrian F ^m   Jaarsma, Tiny ⁿ   Koglin, Joerg ^o   Konstam, Marvin ^p   Kupfer, Stuart ^q   Maggioni, Aldo P ^r   Mebazaa, Alexandre ^s   Metra, Marco ^t   Nowack, Christina ^u   Pieske, Burkert ^v   Piña, Ileana L ^w   Pocock, Stuart J ^x   Ponikowski, Piotr ^y   Rosano, Giuseppe ^z   Ruilope, Luis M ^aa   Ruschitzka, Frank ^ab   Severin, Thomas ^ac   Solomon, Scott ^ad   Stockbridge, Norman L ^af   Stough, Wendy Gattis ^ag   Swedberg, Karl ^ah   Tavazzi, Luigi ^ai   Voors, Adriaan A ^aj   Wasserman, Scott M ^ak   Woehrle, Holger ^al   Zalewski, Andrew ^ac   McMurray, John J V ^am   more..

^a UNIVERSITÉ DE LORRAINE   (France)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF ALBERTA   (Canada)

^e HOSPITAL CLÍNIC   (Spain)

^f CASTLE HILL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF GOTHENBURG   (Sweden)

^k NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^l NORTHWESTERN UNIVERSITY   (United States)

^m DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁿ LINKÖPING UNIVERSITY   (Sweden)

^o MERCK RESEARCH LABORATORIES   (United States)

^p TUFTS UNIVERSITY   (United States)

^q TAKEDA PHARMACEUTICALS   (United States)

^r ANMCO RESEARCH CENTER   (Italy)

^s HÔPITAL LARIBOISIÈRE   (France)

^t UNIVERSITY OF BRESCIA   (Italy)

^u BAYER PHARMA AG   (Germany)

^v MEDICAL UNIVERSITY OF GRAZ   (Austria)

^w MONTEFIORE MEDICAL CENTER   (United States)

^x LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^y WROCLAW MEDICAL UNIVERSITY   (Poland)

^z IRCCS SAN RAFFAELE PISANA   (Italy)

^aa HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ab UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^ac NOVARTIS PHARMA AG   (Switzerland)

^ad BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ae BOSTON SCIENTIFIC CORPORATION   (United States)

^af CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^ag CAMPBELL UNIVERSITY   (United States)

^ah SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ai MARIA CECILIA HOSPITAL   (Italy)

^aj UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ak AMGEN INC   (United States)

^al ResMed   (Germany)

^am UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

Clinical trials; Heart failure; Morbidity; Mortality

Indexed keywords

BIOLOGICAL MARKER;

ACUTE HEART FAILURE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; HEALTH STATUS; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MEDICAL SOCIETY; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

CLINICAL TRIALS; HEART FAILURE; MORBIDITY; MORTALITY;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HOSPITALIZATION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE;

EID: 84885025341     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft095     Document Type: Review

References (112)

1. Armstrong PW, Ezekowitz JA. Testosterone therapy in women with heart failure: 'Why can't a woman be more like a man?'. J Am Coll Cardiol 2010;56:1317-1319.
2. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009;53:2248-2258.
3. Felker GM, Anstrom KJ, Rogers JG. Aglobal ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail 2008;14:368-372. (Pubitemid 351749834)
4. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, YancyCW, Zannad F, Gheorghiade M. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3:314-325.
5. Felker GM, Maisel AS.Aglobal rank end point for clinical trials in acute heart failure. Circ Heart Fail 2010;3:643-646.
6. Hauptman PJ. Measurement of end points in heart failure trials: jousting at windmills? Mt Sinai J Med 2004;71:298-304. (Pubitemid 39440151)
7. Neaton JD, GrayG, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail 2005;11:567-575. (Pubitemid 41463726)
8. Cubbon RM, Gale CP, Kearney LC, Schechter CB, BrooksbyWP, Nolan J, Fox KA, Rajwani A, BaigW, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, Sapsford RJ, Wheatcroft SB, Witte KK, KearneyMT. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011;4:396-403.
9. Solomon SD,Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on causespecific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110:2180-2183. (Pubitemid 39372498)
10. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr., Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
11. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, Neal B, Reidies H, Santarelli L, Schroyer R, Stockbridge NL, Feng Z. Do we need to adjudicate major clinical events? Clin Trials 2008;5:56-60. (Pubitemid 351412373)
12. Pogue J,Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009;6:239-251.
13. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001;2:180-186. (Pubitemid 32780805)
14. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001;2:187-194. (Pubitemid 32780806)
15. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 2002;143:242-248.
16. Naslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebocontrolled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J 1999;20:771-777. (Pubitemid 29209911)
17. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinchak RA, Lee KL, Lamas GA, Mahaffey KW. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006;27:260-268.
18. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (beta-Blocker Evaluation of Survival Trial [BEST]). Am Heart J 2010;160:649-654.
19. Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2329-2334. (Pubitemid 41785506)
20. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
21. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Pina I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010;159:841-849.
22. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-1405.
23. Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJ, Cowley AJ, Dargie HJ, Hall AS, Hampton JR, Poole-Wilson PA. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996;17:1390-1403.
24. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146. (Pubitemid 47311002)
25. McDonagh TA, Komajda M, Maggioni AP, Zannad F, Gheorghiade M, Metra M, Dargie HJ. Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. Eur J Heart Fail 2011;13:1253-1260.
26. Roger VL,GoAS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB,Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics- 2012 update: a report from the American Heart Association. Circulation 2012; 125:e2-e220.
27. Hall M, Levant S, DeFrances C. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief 2012;108:1-8.
28. Fang J, Mensah GA, Croft JB, KeenanNL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428-434. (Pubitemid 352040814)
29. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-371. (Pubitemid 35190362)
30. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, Kirk JD, Miller CD, Nowak R, Peacock WF, Tavares M, Mebazaa A, Gheorghiade M. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 2010; 12:1253-1260.
31. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. Arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675. (Pubitemid 33126822)
32. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, ZarebaW. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
33. Hicks K, Hung H, Mahaffey K, Mehran R, Nissen SE, Stockbridge N, Targum S, Temple R. Standardized definitions for end point events in cardiovascular trials. http://www.cdisc.org/stuff/contentmgr/files/0/ 2356ae38ac190ab8ca4ae0b222392b37/ misc/cdisc-november-16-2010 pdf 2010.
34. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007; 167:1493-1502. (Pubitemid 47134697)
35. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, NielsenOW, Zannad F, Tavazzi L. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076-1084.
36. Bueno H, Ross JS, Wang Y, Chen J, Vidan MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010;303:2141-2147.
37. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, AbrahamWT, Berkowitz RL, Galvao M, HortonDP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216. (Pubitemid 40348525)
38. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011;37:619-626.
39. Eapen Z, Reed S, Yanhong L, Armstrong P, Starling R, McMurray J, Massie B, Swedberg K, Ezekowitz J, Fonarow G, Teerlink J, Metra M, Whellan D, O'Connor C, Califf R, Hernandez A. Do countries or hospitals with longer stays have lower readmission rates? Findings from the ASCEND-HF trial [abstract]. J Am Coll Cardiol 2012;59:E1029.
40. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T. Acute decompensated heart failure syndromes (ATTEND) registry.Aprospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010;159:949-955.
41. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Nunez E, Yancy CW, Young JB. Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Circ Heart Fail 2008;1:50-57.
42. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
43. Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA, Follath F. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 2008;29:413-421. (Pubitemid 351197762)
44. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Gabriel SP, WijnsW, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM,Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, AlmahmeedW, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de LJ, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551-2567.
45. Anker SD, McMurray JJ. Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? Eur Heart J 2012;33:2764-2765.
46. Rogers J, McMurray J, Pocock S, Zannad F, Krum H, van Veldhuisen D, Swedberg K, Shi H, Vincent J, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms: Analysis of repeat hospitalisations. Circulation 2012;126:2317-2323.
47. Pocock SJ, Ariti CA, Collier TJ,Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012;33:176-182.
48. Rogers JK, Pocock SJ, McMurray JJV, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon S, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARMPreserved. Eur J Heart Fail 2013;in press.
49. Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2011;162:900-906.
50. Cleland JG. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 2002;4:243-247. (Pubitemid 35190346)
51. Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, Di LA, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the 'patient journey') in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 2006;47:1603-1611.
52. Borer JS,BohmM, Ford I,Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa E, Swedberg K. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012;33:2813-2820.
53. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure associated hospitalizations in the United States. J Am Coll Cardiol 2013;61:1259-1267.
54. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'ConnorCM,Pieper K, Sun JL, YancyCW, Young JB. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168:847-854. (Pubitemid 351649267)
55. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, O'Connor CM. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure-association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010;115:29-36.
56. Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, Tu JV, StukelTA. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail 2010;3:228-235.
57. Anstrom KJ, Eisenstein EL. From batting average to wins above replacement to composite end points-refining clinical research using baseball statistical methods. Am Heart J 2011;161:805-806.
58. ArmstrongPW,Westerhout CM, Van deWerf F, Califf RM,Welsh RC, Wilcox RG, Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 2011;161:848-854.
59. Bakal JA, Westerhout CM, Armstrong PW. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Stat Methods Med Res 2012;in press.
60. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805. (Pubitemid 46456378)
61. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE-HF. Circ Heart Fail 2008;1:98-106.
62. Ector H, Vardas P. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Eur Heart J Suppl 2007;9:I44-I49.
63. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591-2596. (Pubitemid 39453007)
64. Gilliam FR, Hayes DL, Boehmer JP, Day J, Heidenreich PA, Seth M, Jones PW, SteinKM, Saxon LA. Realworld evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011;22:1023-1029.
65. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J AmColl Cardiol 2008;51:1357-1365. (Pubitemid 351443082)
66. van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van EL, Bax JJ, Schalij MJ. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556-562.
67. Powell BD, Cha YM, Asirvatham SJ, Cesario DA, Cao M, Jones PW, Seth M, Saxon LA, Gilliam FR III. Implantable cardioverter defibrillator electrogram adjudication for device registries: methodology and observations fromALTITUDE. Pacing Clin Electrophysiol 2011;34:1003-1012.
68. Blair JE, Zannad F, Konstam MA, CookT, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, ZimmerC, Gheorghiade M. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008;52:1640-1648.
69. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463. (Pubitemid 36286187)
70. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Court, Hasa J, Spinar J, Masip J, Frank PW, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-841.
71. West RL, Hernandez AF, O'Connor CM, Starling RC, Califf RM. A review of dyspnea in acute heart failure syndromes. Am Heart J 2010;160:209-214.
72. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008;29:816-824. (Pubitemid 351431028)
73. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr., Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
74. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O'Connor CM, Ponikowski P. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 2013; 15:456-464.
75. Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129-1133. (Pubitemid 17158144)
76. Grant S, Aitchison T, Henderson E,Christie J, Zare S,McMurray J, Dargie H.Acomparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999;116:1208-1217. (Pubitemid 29535970)
77. PeacockW, Mebazaa A. Clevidipine improves dyspnea in emergency department acute heart failure a randomized, open-label study [abstract]. Circulation 2012; in press.
78. Ekman I, Kjork E, Andersson B. Self-assessed symptoms in chronic heart failure- important information for clinical management. Eur J Heart Fail 2007;9:424-428. (Pubitemid 46441979)
79. Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Guidance for Industry 2009.
80. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity-establishing and reporting the evidence in newly developed patient- reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health 2011;14:967-977.
81. Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, Van GE, Alonso J. Diseasespecific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res 2009;18:71-85.
82. Cella D, RileyW, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M,Weinfurt K, HaysR. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010;63:1179-1194.
83. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www fda gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM193282 pdf 2009.
84. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Reflection paper on the regulatory guidance for the use of healthrelated quality of life measures in the evaluation of medicinal products. http:// www ema europa eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003637 pdf 2005.
85. Ekman I, Cleland JG, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail 2005;11:288-292. (Pubitemid 40616899)
86. Lupon J, Gastelurrutia P, de AM, Gonzalez B, Cano L, Cabanes R, Urrutia A, Diez C, Coll R, Altimir S, Bayes-Genis A. Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. Eur J Heart Fail 2013;15: 103-109.
87. Cohn J, Cleland JG, Lubsen J, Borer JS, Steg PG, Perelman M, Zannad F. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? J Card Fail 2009;15:199-205.
88. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176-182. (Pubitemid 32554111)
89. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M,Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
90. Edelmann F, Gelbrich G, Dungen HD, Frohling S, Wachter R, Stahrenberg R, Binder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Loffler M, Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58:1780-1791.
91. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ,Waldenstrom A,Warren M,Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602. (Pubitemid 38451714)
92. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, doubleblind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140. (Pubitemid 36793081)
93. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 + -ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.
94. Kaul S, Diamond GA. Trial and error.Howto avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010;55:415-427.
95. Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Antithrombotic outcome trials in acute coronary syndromes seeking the optimal balance between safety and efficacy. Eur Heart J 2013;in press.
96. Zannad F, StoughWG,Pocock SJ, Sleight P,CushmanWC,Cleland JG, McMurray JJ, Lonn E, Geller NL,Wedel H, Abadie E, Alonso-Garcia A, Pitt B. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J 2012;33:1049-1057.
97. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891. (Pubitemid 46707842)
98. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011;32:2563-2572.
99. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-1222.
100. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689. (Pubitemid 30167025)
101. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, RichMW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-67. (Pubitemid 38045917)
102. Gottlieb SS, AbrahamW, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141. (Pubitemid 34857278)
103. Collins SP, Hart KW, Lindsell CJ, Fermann GJ, Weintraub NL, Miller KF, Roll SN, Sperling MI, Sawyer DB, Storrow AB. Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail 2012; 14:1020-1029.
104. Jose P, Tomson C, Skali H, Rouleau J, Braunwald E, Arnold JM, Cuddy T, Sussex B, Bernstein V, Pfeffer M, Solomon S. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol 2006;47:1725-1727.
105. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol 2011;58:1958-1966.
106. Vardeny O,WuDH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from the Randomized Aldactone Evaluation Study. J Am Coll Cardiol 2012.
107. Braunwald E. Heart failure. J Am Coll Cardiol HF 2013 1 1-20.
108. Nikolaou M, Parissis J, Yilmaz MB, SerondeMF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013;34:742-749.
109. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr., Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
110. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003;145:S26-S33. (Pubitemid 36207922)
111. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019. (Pubitemid 350074798)
112. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.